@LordGrimdark@GigameshTienda After seeing this tweet I hustled across the city and made it in time to meet my favourite author in person. Thank you for signing my e-reader, @LordGrimdark :)
🌟After an incredible 10 years, we bid a fond farewell to @DrRomanBelle as he embarks on an exciting new chapter! Roman’s contributions to our chemical biology research, his scientific insight and dedication have left a lasting mark on our work. 🌟
In our chem bio research groups, we are committed to fostering an inclusive environment where everyone can thrive and make a difference. Special thanks to all the women in the Kawamura Research Group and @mcallister_lab for their contributions to the field of science! #IDWGS2025
The cost of #Wegovy to prevent one stroke in the US is double what’s paid by Britain’s health service, reveals new analysis by Airfinity.
Read our feature in @Bloomberg to find out more.
https://t.co/gUi4M8Snzp
Join our @ScienceUnga Webinar: Data for Pandemic Preparedness: New approaches for medical countermeasure (MCM) delivery
Live next Wednesday 18th September 2024, 3pm ET/ 8pm BST.
Register for free through the UNGA Science Summit online portal below.
https://t.co/7M2NFxTNoX
Today I finally got to witness chaos with Ed Miliband. Quite orderly actually.
Don't forget your photo ID when you vote #Labour on July 4th. It's rose season 🌹🌹🌹🌹🌹
Compass Oxon had a fabulous day yesterday campaigning in Banbury for voters to support @UKLabour candidate, @SEANLWOODCOCK. Bravo and a huge thank you to everyone involved. #WinAsOne
@skathire Probably, given the association between obesity and HFpEF, although the negative RELIVE-HF trial presented at a late breaking session yesterday showed that even a regimen that increases mortality risk in HFpEF could lead to increased KCCQ!
Today, @VerveTx is announcing updates to our PCSK9 program:
1. voluntarily pausing enrollment in the Heart-1 trail of VERVE-101
2. prioritizing clinical development of VERVE-102 which uses a different LNP delivery system
3. announcing clinical trial application have been cleared in U.K. & Canada for Heart-2 trial of VERVE-102
4. expect initiation of Heart-2 trial this quarter
Details:
1. 13 patients dosed so far in Heart-1 trial, 6 at 0.45 mg/kg dose
2. Efficacy: up to 73% reduction in LDL-C and durability out to 270 days after single treatment
3. However, at potentially therapeutic doses, seeing laboratory abnormalities
4. last patient dosed at 0.45 mg/kg experienced a Grade 3 drug-induced transient increase in serum alanine aminotransferase as well as a serious adverse event of Grade 3 drug-induced thrombocytopenia (a drop in the platelet count)
5. Lab changes transient, reversible, asymptomatic
6. Nevertheless, have elected to pause enrollment to investigate in order understand mechanism, if means to mitigate
7. Regulators informed; IND, CTAs for Heart-1 trial remain active
8. We believe lab safety findings attributable to lipid nanoparticle delivery system
9. For now, prioritizing development of VERVE-102
10. VERVE-102 uses an LNP with an ionizable lipid that has been tested in third-party clinical trials and well-tolerated
11. VERVE-102 also adds a GalNAc liver-targeting ligand
12. Expect to start Heart-2 trial of VERVE-102 in 2Q '24
Link to PR: https://t.co/GpkMT8eZIB
Had an excellent time at the @BriTANicK show yesterday at the @sohotheatre! An absolutely fantastically crafted show, go see them if you get the chance!
Also, bonus run-in with @TheJacobTrueman of the Fratocrats :)
UK plant science twitter, can you help? Is anyone growing whole cell Arabidopsis thaliana cultures and would be happy to share some with us? Ours sadly died but we need some for more experiments! Many thanks :-)